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Previous studies related impaired myocardial microcirculation in diabetes to oxidative stress and endothelial dysfunction. Thus, this study
was aimed to determine the effect of up-regulating pAMPK-pAKT signaling on coronary microvascular reactivity in the isolated heart of
diabetic mice. We measured coronary resistance in wild-type and streptozotocin (STZ)-treated mice, during perfusion pressure changes.
Glucose, insulin, and adiponectin levels in plasma and superoxide formation, NOx levels and heme oxygenase (HO) activity in myocardial
tissue were determined. In addition, the expression of HO-1, 3-nitrotyrosine, pLKB1, pAMPK, pAKT, and peNOS proteins in control and
diabetic hearts were measured. Coronary response to changes in perfusion pressure diverged from control in a time-dependent manner
following STZ administration. The responses observed at 28 weeks of diabetes (the maximum time examined) were mimicked by L-NAME
administration to control animals and were associated with a decrease in serum adiponectin and myocardial pLKB1, pAMPK, pAKT, and
pGSK-3 expression. Cobalt protoporphyrin treatment to induce HO-1 expression reversed the microvascular reactivity seen in diabetes
towards that of controls. Up-regulation of HO-1 was associated with an increase in adiponectin, pLKB1, pAKT, pAMPK, pGSK-3, and peNOS
levels and a decrease in myocardial superoxide and 3-nitrotyrosine levels. In the present study we describe the time course of microvascular
functional changes during the development of diabetes and the existence of a unique relationship between the levels of serum adiponectin,
pLKB1, pAKT, and pAMPK activation in diabetic hearts. The restoration of microvascular function suggests a new therapeutic approach to
even advanced cardiac microvascular derangement in diabetes. J. Cell. Biochem. 109: 1033–1044, 2010.  2010 Wiley-Liss, Inc.KEY WORDS: CORONARY MICROCIRCULATION; DIABETIC CARDIOMYOPATHY; HEME-OXYGENASE-1; ENDOTHELIAL DYSFUNCTION; ADIPONECTINW e have previously employed the isolated heart inLangendorff configuration to investigate coronary micro-
vascular reactivity in rodents [Kusmic et al., 2006; L’Abbate et al.,
2007]. In spite of the limitations of the isolated heart preparation (no
blood perfusion, loss of basal coronary tone, uncertain equivalence
with in vivo conditions), the vasoconstrictive response to transiently
reduced perfusion pressure appears to be a simple, reliable way to
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vasodilation elicited by ischemia (low flow and lactate release),
mimics the vasoconstrictive response observed downstream a
severe stenosis in patients with chronic angina, during pacing-
induced ischemia [Sambuceti et al., 1997, 2001, 2005]. Importantly,
the active nature of this phenomenon (increased vascular tone
as opposed to increased intramural vascular compression) was
demonstrated in the mouse by its relief following papaverine1033
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injection [Kusmic et al., 2006]. In the wild-type mouse, ‘‘paradoxical
vasoconstriction’’ appeared to be dependent upon endothelial
NO production and reactive oxygen species (ROS). In particular,
administration of L-NAME, an inhibitor of nitric oxide synthase
(NOS), reversed ‘‘paradoxical’’ vasoconstriction to vasodilation and
ROS scavengers suppressed the vasoconstrictive response suggest-
ing that the combination of NO and ROS is essential for eliciting
vasoconstriction during hypotension.
Microvascular reactivity was also examined during perfusion at
‘‘normal’’ pressure and coronary resistance remained constant
in untreated heart while progressively increasing during
L-NAME administration. We speculated that an unknown long-
acting vasoconstrictor(s), accumulates with time [Kusmic et al.,
2006] and showed in the isolated heart of wild-type mouse, L-NAME
exerted a second apparently opposite role of NO, namely mediating
vasoconstriction in response to low perfusion pressure while
contrasting vasoconstriction at ‘‘normal’’ perfusion pressure.
Adipose tissue plays an important role in insulin resistance
through the secretion of a variety of proteins such as TNF-a, IL-6,
leptin, and adiponectin [Berg and Scherer, 2005]. In particular,
adiponectin has attracted considerable attention as it has insulin-
sensitizing properties that reduce serum triglyceride levels, enhance
fatty acid oxidation and glucose uptake in the liver [Berg et al.,
2001; Kim et al., 2007]. It has been suggested that adiponectin acts
through the AMPK signaling pathway in the vasculature [Chen et al.,
2003]. Activated AMPK and AKT have been identified as regulators
of endothelial cell nitric oxide synthase (eNOS) activation as well as
a number of cellular responses [Fleming et al., 2003; Kovacic et al.,
2003; Ouchi et al., 2004; Skurk et al., 2004; Sun et al., 2005; Reihill
et al., 2007]. Because AMPK has been identified as a potential target
for the treatment of type 2 diabetes [Musi and Goodyear, 2002] and
we previously observed that an increase in cardiac HO-1 levels
increases serum adiponectin and myocardial pAKT in both control
and diabetic rats [L’Abbate et al., 2007], a central issue in the present
study was to determine whether the diabetic state is associated
with abnormalities in upstream and downstream AMPK signaling
pathway.
We hypothesized that progressive loss of NO in the diabetic heart
would modify coronary reactivity in a manner similar to L-NAME in
control heart and that activation of heme oxygenase-1 (HO-1) would
restore control vasoreactivity by enhancing NO and reducing
ROS. We examined coronary reactivity in mice with streptozotocin
(STZ)-induced non-insulin-dependent diabetes, with three main
objectives: firstly, to define the time course of changes in coronary
microvascular reactivity during development of diabetes, secondly,
to investigate the molecular mechanisms involved in vasoreactivity,
in particular NO production and availability, and oxidative
stress; thirdly, to assess the efficacy of HO-1 induction in restoring
normal microvascular response, HO-1 is down-regulated in
diabetic heart and induction results in increased adiponectin levels
and enhanced heart tolerance to ischemia [L’Abbate et al.,
2007].
We report a progressive deviation from normal of coronary
microvascular reactivity in the diabetic heart that developed with
time irrespective of constant hyperglycemia, insulinemia, and of
glucose intolerance. Both systemic and coronary alterations are1034 HO-1 SIGNALING IN CORONARY MICROCIRCULATIONprevented by the HO-1 mediated increase in myocardial pLKB1,
pAMPK, pAKT, and peNOS levels.
MATERIALS AND METHODS
Surgical procedures and experimental protocols were approved by
the Animal Care Committee of the Italian Ministry of Health and
conformed to the ‘‘Guiding Principles for Research Involving
Animals and Human Beings’’ approved by the Council of the
American Physiological Society. All mice were housed under
controlled 12/12 h light/dark cycle and given food and water ad
libitum.
ANIMAL MODELS
Male C57BL/6 6- to 8-week-old mice (Harlan, Italy) were
administered an intraperitoneal (i.p.) low-dose injection of STZ to
induce diabetes by adapting the protocol used by members of the
Animal Models of Diabetic Complication Consortium (USA). Briefly,
STZ was made fresh daily and dissolved in 0.05 mol/L citrate buffer
(pH 4.4) at a concentration of 5 mg/ml and injected i.p. at the dose of
35 mg/kg body weight for five consecutive days to obtain a stable
animal model of experimental, non-insulin-dependent diabetes.
Diabetic mice were studied at 28 weeks following STZ
administration, a result of a preliminary study, carried out at 6,
9, and 28 weeks, aimed at assessing the time course of coronary
changes during development of diabetes. At 28 weeks (about one-
third of the normal life span of mice) microvascular reactivity
maximally diverged from that of control animals. Moreover, out of
the STZ-treated animals only those showing glucose plasma levels
of 180–250 mg/dl and insulin plasma values of 0.7–1.1mg/L which
better mimic the systemic humoral picture of patients with type 2
diabetes.
According to the above criteria, 49 diabetic mice were studied of
which 20 did not receive any other treatment following STZ
administration. Seventeen mice were treated with cobalt proto-
porphyrin (CoPP) in order to test the effect of the pharmacological
up-regulation of HO-1 expression and the remaining 12 received an
infusion of L-NAME during perfusion in the Langendorff config-
uration in order to investigate the effect of NO deprivation on
microvascular reactivity. Forty-seven control mice, age and gender
matched to diabetic mice, were treated with citrate buffer solution
and examined at the same time points as the diabetic animals.
The increased expression of HO-1 in diabetic and control
groups was pharmacologically induced by administering a dose of
1.5 mg/100 g body weight of CoPP subcutaneously every five days
for a total of three injections. Tin protoporphyrin IX (SnPPIX), a
selective inhibitor of HO activity, was administered i.p. at the dose of
2.0 mg/100 g body weight to CoPP-treated animals, 24 h before
heart’s explant, in order to distinguish the specific effect of increased
HO activity on the parameters under investigation.
In all animals, blood samples were collected weekly from the tail
vein following a 4 h period of fasting to measure glucose levels
(Glucocard GT-1610, Menarini Diagnostic, Firenze, Italia). Insulin
levels were determined by ELISA (Mouse Insulin ELISA, Mercodia,
Uppsala, Sweden) in serum samples collected before STZ treatmentJOURNAL OF CELLULAR BIOCHEMISTRY
(basal level) and at the time of sacrifice. Animals, randomly chosen
from all groups, underwent a glucose tolerance test. The test was
performed on awake mice that were fasted for 6 h and injected with a
glucose solution. A 100 mg/ml glucose stock solution was prepared
in distilled water and sterilized by passing through a 0.2mm filter.
Following baseline blood glucose measurement, each mouse was
challenged with a 1 mg glucose/gram body weight. Post-injection
blood glucose measurements were performed at 10, 20, 30, 60, and
120 min after glucose loading.
ISOLATED HEART PREPARATION
Animals were heparinized (500 U i.m.) 10 min prior to anesthesia
with pentobarbitone sodium (40 mg/kg, i.p.). Hearts were excised
and placed in ice-cold Krebs–Henseleit bicarbonate solution of the
following composition (mmol/L): 118 NaCl, 24 NaHCO3, 4.7 KCl,
1.2 KH2PO4, 1.2 MgSO4, 2.5 CaCl2, 0.5 EDTA, and 5.5 glucose. The
solution was pre-equilibrated with 95% O2 and 5% CO2 at pH 7.4.
Extraneous tissues were removed, and the aorta was cannulated with
a 20-gauge plastic cannula. The heart was then transferred to a
modified non-recirculating Langendorff apparatus where it was
allowed to beat spontaneously. Myocardial and buffer temperatures
were kept constant at 378C. Two side-arms in the perfusion line,
located close to the heart inlet, allowed switching between two
reservoirs set at ‘‘normal’’ (65 mmHg) and ‘‘low’’ (30 mmHg)
pressure. Coronary flow was continuously measured with a
flowmeter (model T106, Transonic System, Inc., Ithaca, NY) coupled
to a in-line flow probe. The volume of effluent was also measured
with a calibrated pipette as an additional estimate of coronary flow.
Coronary resistance was calculated as input pressure divided by
coronary flow per gram of myocardial tissue (mmHg g min/ml).
After an initial 10-min period of stabilization, not included in the
analysis, two different protocols each of 70 min duration were
followed:
Protocol 1—Control pressure: Preparations were maintained at
65 mmHg input pressure during the entire 70 min experiment. A
bolus of papaverine (50mg) was used to examine the nature of
coronary resistance by releasing vascular smooth muscle to
document active vasoconstriction.
Protocol 2—Transient hypotension: Input pressure was reduced
from 65 to 30 mmHg at the 20 min mark for a period of 20 min and
then restored to 65 mmHg for the remaining 30 min.
In control animals (n¼ 12) as well as in diabetic animals (n¼ 12)
L-NAME was added to the perfusion medium to a final concentra-
tion of 100mmol/L at the time of aorta cannulation and remained in
the preparation for the entire experiment in both protocol 1 and 2.
At the end of constant pressure experiments, hearts were rapidly
frozen in liquid nitrogen and stored at 808C.
WESTERN BLOT ANALYSIS OF CARDIAC TISSUE
Frozen hearts, obtained from animals perfused according to the
constant pressure protocol, were pulverized under liquid nitrogen
and placed in a homogenization buffer (in mmol/L: 10 phosphate
buffer, 250 sucrose, 1 EDTA, 0.1 PMSF, and 0.1%, v/v, tergitol, pH
7.5). Homogenates were centrifuged at 27,000g for 10 min at 48C,
supernatant was isolated, and protein levels were visualized by
immunoblotting with antibodies against HO-1, and HO-2 (StressgenJOURNAL OF CELLULAR BIOCHEMISTRYBiotechnologies Corp., Victoria, BC). Antibodies against LKB1, AKT,
AMPK, pLKB1(Ser 428), pAMPK(Thr 172), pAKT(Ser 473), pGSK-
3(Ser 9), 3-Nitrotyrosine (3-NT) (Cell Signaling Technology, Inc.,
Beverly, MA) eNOS, peNOS(Ser 1177), and b-actin (Santa Cruz
Biotechnology, Santa Cruz, CA) were used. Myocardial b-actin
expression was used as comparative protein. Antibodies were
prepared in the following dilutions: HO-1, HO-2, and 3-NT 1:1000,
eNOS, peNOS, LKB1, pLKB1, AMPK, pAMPK, AKT, pAKT, and pGSK-
3 1:5000.
Briefly, 20mg of heart tissue lysate supernatant was separated by
12% SDS/polyacrylamide gel electrophoresis and transferred to a
nitrocellulose membrane. Immunoblotting was performed as
previously described [Abraham et al., 2003]. Chemiluminescence
detection was performed with the Amersham ECL detection kit
(Amersham, Piscataway, NJ), according to the manufacturer’s
instructions.
DETERMINATION OF HO ACTIVITY
Frozen hearts were pulverized under liquid nitrogen and placed in
homogenization buffer (in mmol/L: 10 phosphate buffer, 250
sucrose, 1 EDTA, 0.1 PMSF, and 0.1%, v/v, tergitol, pH 7.5).
Homogenates were centrifuged at 27,000g for 10 min at 48C. Heme
oxygenase activity was determined using a scanning double beam
spectrophotometer (Lambda 17 UV/Vis; Perkin Elmer Cetus
Instruments, Norfolk, CT) and expressed as nmol bilirubin/mg
protein/h. Bilirubin formation was calculated using an extinction
coefficient of 40 mmol/L1 cm1 between 464 and 530 nm.
MEASUREMENT OF HEART O-2 AND NO METABOLITES
(NOx) LEVELS
Control and diabetic hearts were placed in plastic scintillation
minivials containing 5mmol/L lucigenin for detection of O2 , in a
final volume of 1 ml of air-equilibrated Krebs solution buffered with
10 mmol/L HEPES-NaOH (pH 7.4) as previously described [Abraham
et al., 2003]. Lucigenin chemiluminescence was measured in a liquid
scintillation counter (LS6000IC, Beckman Instruments, San Diego,
CA). NOx levels were evaluated by measuring total nitrite and nitrate
content in heart tissue homogenate using a NOx quantitation kit and
following the manufacturer’s instruction (Active Motif, Carlsbad,
CA).
SERUM ADIPONECTIN MEASUREMENTS
The high molecular weight form of adiponectin was determined
using an ELISA assay (Pierce Biotechnology, Inc., Woburn, MA).
DRUGS AND CHEMICALS
STZ and L-NAME were purchased from Sigma (St. Louis, MO).
Papaverine was purchased from Monico (Venezia, Italy). CoPP was
purchased from Frontier Scientific (Logan, UT). Tin protoporphyrin
IX was provided as a generous gift from A. Kappas, MD (Rockefeller
University, New York, NY).
All the other chemicals used were purchased from Sigma and
were of reagent grade.HO-1 SIGNALING IN CORONARY MICROCIRCULATION 1035
STATISTICAL ANALYSIS
The data are presented as mean SE. Statistical significance of
differences between groups was determined by ANOVA followed by
post hoc Fisher’s test or by paired and unpaired Student’s t-test as
appropriate. A probability (P) value of <0.05 was taken to indicate
statistical significance.
RESULTS
TIME COURSE OF MICROVASCULAR REACTIVITY FOLLOWING
STZ ADMINISTRATION
As shown in Figure 1, the coronary resistance response to both
constant pressure and transient low pressure differed at differentFig. 1. Coronary microvascular resistance in protocol 1 (perfusion at
65 mmHg constant pressure), gray circles, as compared to protocol 2 (transient
30 mmHg perfusion pressure), black circles, in controls and in diabetic animals
at 6, 9, and 28 weeks following STZ or vehicle administration. Dashed vertical
lines mark the period of low pressure in protocol 2. A: Control group (gray
n¼ 11 and black n¼ 9). Controls have been pooled together as no differences
were apparent at 6, 9, and 28 weeks. B: Six-week diabetic mice (gray n¼ 6 and
black n¼ 5). C: Nine-week diabetic mice (gray n¼ 5 and black n¼ 6).
D: Twenty-eight-week diabetic mice (gray n¼ 11 and black n¼ 10). Inset
shows the effect of administration in bolus (arrow) of papaverine in 28-week
diabetic mouse during protocol 1 (constant pressure perfusion).
1036 HO-1 SIGNALING IN CORONARY MICROCIRCULATIONtimes (6, 9, and 28 weeks after STZ administration), progressively
diverging from time-matched controls, with a maximum divergence
at 28 weeks. At constant pressure (gray symbols) a progressive
increase in resistance was observed during the 70 min of perfusion.
The magnitude of vasoconstriction significantly increased from 6 to
28 weeks. As already reported for control animals [Kusmic et al.,
2006], a bolus administration of papaverine (50mg), abolished the
increase in resistance in diabetic mice (Fig. 1D, inset) proving its
active nature and ruling out the intervention of extra-vascular
compressive forces.
During low-pressure perfusion (black symbols) the paradoxical
vasoconstriction observed in control animals was blunted at 6 weeks
and progressively reversed to vasodilation at 28 weeks (Fig. 1). On
the basis of these results, the present studies employed diabetic
animals 28 weeks after STZ treatment.
EFFECT OF CHRONIC DIABETES ON BODY WEIGHT, PLASMA
GLUCOSE, AND INSULIN LEVELS
As seen in Table I, no significant difference in body weight and
plasma insulin levels between control and diabetic mice was
observed. Plasma glucose levels in diabetic mice were significantly
higher than in control mice (P< 0.001). In contrast treatment of
diabetic mice with CoPP reduced glucose in plasma to the levels of
the control group. CoPP treatment in control mice did not affect
either fasting glucose or insulin levels.
EFFECT OF CHRONIC DIABETES ON GLUCOSE TOLERANCE TEST
As expected, in control animals, glucose loading produced a marked
increase in glucose levels that peaked at 20 min at around 300 mg/dl,
thereafter progressively declining towards initial levels (Table II).
However, in diabetic mice, glucose tolerance curves were typical of
glucose intolerance, commencing at basal levels that were higher
than in age-matched controls, glucose levels peaked 20–30 min after
glucose infusion at values of 466 mg/dl and above and remained
elevated (over 300 mg/dl) for the duration of the experiment.
Glucose values in diabetic mice were statistically higher than in
control animals (P< 0.001).
The effect of HO-1 expression on chronic diabetes and glucose
tolerance, is shown in Table II. Diabetic mice treated with CoPP
showed a marked decline in fasting plasma glucose levels to values
no different from those seen in control animals. In addition, glucose
levels during the glucose tolerance test were significantly reduced in
diabetic mice following CoPP administration compared to untreated
diabetic mice (P< 0.001). CoPP administered to control animals
significantly impaired the glucose rise during the glucose tolerance
test relative to untreated control animals (P< 0.001).
EFFECT OF DIABETES ON CORONARY RESISTANCE IN HEARTS
UNDER CONSTANT PRESSURE
Control hearts perfused at constant pressure exhibited relatively
stable coronary resistance with only a small increase detectable over
the study period (from 5.6 0.4 to 7.1 0.3 mmHg min g ml1 at 0
and 70 min, respectively; P< 0.05) (Fig. 1A and inset of Fig. 2A). In
diabetic mice, the initial values of coronary resistance were similar
to those in the control group. However, coronary resistance
increased throughout the perfusion period in diabetic hearts,JOURNAL OF CELLULAR BIOCHEMISTRY
TABLE I. General Characteristics of Experimental Animals
Group n Body weight (g) Plasma glucose (mg/dl) Plasma insulin (mg/L)
Control 20 31 2.4 131 7.8 0.86 0.1
Diabetes 20 33 1.1 232 27 0.83 0.3
Effect of CoPP treatment
ControlþCoPP 9 31 4.0 135 11 0.88 0.3
DiabetesþCoPP 17 34 1.4 142 5.0y 0.77 0.1
Values are mean SE; n, number of animals tested. Animals were examined and treated with CoPP 28 weeks after citrate buffer (control) or STZ (diabetes) administration.
P< 0.001 versus control.
yP< 0.001 versus untreated diabetes.attaining values significantly higher (P< 0.05) than those observed
in controls starting from 18 min. At 70 min coronary resistance
achieved values of 14.4 0.3 mmHg min g ml1 (P< 0.005 vs.
controls) (Fig. 2A).EFFECT OF DIABETES ON CORONARY RESISTANCE IN HEARTS
UNDER LOW FLOW ISCHEMIA
In control hearts hypotension caused a marked increase in coronary
resistance (paradoxical vasoconstriction) (Fig. 1A and inset of
Fig. 2A). The response was biphasic with a rapid initial increase
followed by a slower but progressive increase. At the peak, coronary
resistance rose about 1.9-fold over baseline (P< 0.001). The return
to normal perfusion pressure caused a sudden fall in resistance to a
steady value that was significantly higher than baseline (P< 0.01).
As shown in Figure 2A, 28 weeks of diabetes resulted in an early
rise in coronary resistance during the first 20 min of the protocol not
dissimilar from that reported in the constant pressure protocol at the
same time points. However hypotension induced a marked drop of
resistance, opposite to the vasoconstriction observed in controls
(compare 2A vs. the inset or Fig. 1A). A subsequent return to normal
perfusion pressure produced a new, steady increase in coronary
resistance up to 1.3-fold of that of control (P< 0.05).EFFECT OF L-NAME ON CORONARY RESISTANCE
In control mice, during constant pressure, a progressive rise in
resistance was observed during infusion of L-NAME (Fig. 2B)
confirming previous results [Kusmic et al., 2006]. This response
closely resembled that recorded in long lasting diabetes (Fig. 2,
compare B vs. A) although the increase in resistance following
L-NAME was significantly higher (P< 0.05) when compared to theTABLE II. Plasma Glucose Level (mg/dl) During Glucose Tolerance
Test
Group n 0 min 20 min 30 min 60 min 120 min
Control 20 131 8.0 301 15 287 14 211 16 160 8.0
Diabetes 20 225 16 466 21 461 24 375 29 303 21
Effect of CoPP treatment
ControlþCoPP 9 135 11§ 182 10§ 169 8.0§ 145 8.0§ 110 5.0§
DiabetesþCoPP 17 142 5.0y 313 15y 276 12y 193 11y 148 6.0y
Values are mean SE; n, number of animals tested. Animals were examined and
treated with CoPP 28 weeks after citrate buffer (control) or STZ (diabetes)
administration.
P< 0.001 versus control.
yP< 0.001 versus untreated diabetes.
§P< 0.001 versus untreated control.
JOURNAL OF CELLULAR BIOCHEMISTRYdiabetic group. The addition of L-NAME to diabetic hearts further
enhanced coronary resistance to values similar to L-NAME-treated
controls (Fig. 2D).
In the low-pressure protocol, L-NAME treatment in control mice
converted the response to hypotension from vasoconstriction to
vasodilation, once again mimicking the response observed in
diabetic mice. However, as for the protocol that utilized constant
pressure, during the initial and latter period of perfusion at
65 mmHg the relative amplitude of vasoconstriction was greater in
L-NAME-treated hearts from control than from diabetic animals
(Fig. 2B). The addition of L-NAME to diabetic hearts resulted in the
response of coronary resistance to hypotension being similar to that
observed in L-NAME-treated controls (Fig. 2D). The relative values
of coronary resistance at 70 min in each protocol were: control L-
NAME> diabetic L-NAME> diabetic> control.
EFFECT OF CoPP ON CORONARY RESISTANCE IN CONTROL AND
DIABETIC ANIMALS
Pre-treatment of control mice with CoPP did not significantly
modify the coronary resistance response that occurred during
constant pressure in the untreated control mice (Fig. 2C, inset).
Conversely, in CoPP pre-treated diabetic mice, coronary resistance
increased less than in untreated diabetic animals (P< 0.05 vs.
untreated diabetics) (Fig. 2C vs. A).
During transient low pressure ischemia, pre-treatment with CoPP
largely abolished the vasoconstrictive response to hypotension in control
mice (inset Fig. 2C) while in diabetic mice it reverted the vasodilator
response seen during hypotension into a vasoconstrictor response
(Fig. 2C). A return to normal perfusion pressure induced a transient
drop in coronary resistance followed by a new progressive increase.
Treatment with SnPPIX, in CoPP-treated diabetic mice 24 h
before heart explant, blunted the effect of CoPP on microvascular
reactivity increasing resistance during constant pressure and
restoring vasodilation during low pressure (results not shown).
EFFECTS OF CoPP ON HEART HO-1 GENE EXPRESSION, HO
ACTIVITY AND SUPEROXIDE LEVELS
Western blot analysis of heart homogenates revealed that levels of
HO-1 protein were significantly decreased in diabetes compared to
control (Fig. 3A). In contrast, significant levels of HO-2 were
detected in control hearts and were no different from HO-2 levels in
diabetic hearts. Thus a significant decrease (P< 0.05) in the ratio of
HO-1 to HO-2 in the hearts of diabetic mice compared to hearts from
control mice was observed. CoPP administration increased heartHO-1 SIGNALING IN CORONARY MICROCIRCULATION 1037
Fig. 2. Coronary microvascular resistance in protocol 1 (perfusion at 65 mmHg constant pressure, gray circles) as compared to protocol 2 (transient 30 mmHg perfusion
pressure, black circles). Dashed horizontal lines are set at 5 and 20 marks on the coronary resistance axis for a better comparison between panels. A: Twenty-eight-week diabetic
mice (gray n¼ 11 and black n¼ 10) already shown in Figure 1A. Inset reproduces the response in control group (gray n¼ 11 and black n¼ 9) for comparison. B: The addition of
the NOS synthase inhibitor L-NAME in controls (gray n¼ 6 and black n¼ 6). C: The effect of CoPP treatment in diabetic mice (gray n¼ 6 and black n¼ 7). Inset reproduces the
effect of CoPP treatment in controls (gray n¼ 6 and black n¼ 9) for comparison. D: The addition of L-NAME to diabetic mice (gray n¼ 6 and black n¼ 6).HO-1 protein levels in diabetic (Fig. 3A) as well as control mice
(P< 0.01 for both) but had no effect on HO-2 protein levels.
HO activity was decreased in diabetic hearts compared to control
hearts (0.43 0.11 nmol bilirubin formed/mg protein/h in diabetes
vs. 0.68 0.12 nmol bilirubin formed/mg protein/h in control,
P< 0.05). HO-1 induction resulted in increased HO activity in the
hearts of diabetic mice following CoPP treatment, (1.51 0.41 nmol
bilirubin formed/mg protein/h), P< 0.05 versus untreated diabetic
hearts.
Measurement of O2 was performed at low concentrations of
lucigenin (5mmol/L). The decrease in cardiac HO-1 levels as a result
of diabetes was associated with a significant reciprocal increase in
O2 (O

2 formed in diabetic heart was 1.2 104 cpm/mg protein
compared to 0.58 104 cpm/mg protein in control hearts, P< 0.05)
(Fig. 3B). However, the increase in HO activity, as a result of CoPP
administration, was associated with a significant decrease in O2 in
diabetic hearts to 0.67 104 cpm/mg protein (P< 0.05 treated vs.
untreated diabetes) (Fig. 3B).1038 HO-1 SIGNALING IN CORONARY MICROCIRCULATIONEFFECT OF CoPP ON SERUM ADIPONECTIN LEVELS
There was a significant decrease in serum adiponectin levels in
diabetic mice compared to age-matched control mice, 2.61
0.23mg/ml versus 4.29 0.36mg/ml (P< 0.01). CoPP administra-
tion resulted in a marked increase (P< 0.001) in the levels of serum
adiponectin in diabetic mice as compared to diabetic untreated mice
(4.4 0.89mg/ml vs. 2.61 0.23mg/ml). Moreover, the increase in
adiponectin levels seen in diabetic mice following CoPP treatment
attained a level similar to that found in control animals (Fig. 3C).
EFFECTS OF PERTURBATION OF HO-1 EXPRESSION ON HEART
3-NITROTYROSINE (3-NT) AND NO METABOLITES (NOx) LEVELS
Densitometry analysis showed detectable levels of 3-NT in hearts of
control mice (Fig. 4A). The 3-NT level increased significantly in
diabetic hearts compared to control hearts (P< 0.05). Following
CoPP treatment the level of 3-NT in diabetic mice was significantly
reduced when compared to that in untreated diabetic animals
(P< 0.05) (Fig. 4A).JOURNAL OF CELLULAR BIOCHEMISTRY
Fig. 3. A: Western blot and densitometry analysis of HO-1, HO-2 and b-actin expression in myocardium of control and diabetic mice untreated or treated with CoPP.
P< 0.01 diabetes versus control, §§P< 0.01 diabetes CoPP versus diabetes. Histograms are mean SE, n¼ 4 in each group. B: Myocardial O2 production in control, diabetic
mice, and diabetic mice treated with CoPP. P< 0.05 diabetes versus control; §P< 0.05 diabetes CoPP versus diabetes. Results are mean SE; n¼ 4 in each group. C: Serum
adiponectin levels in control and diabetic mice, untreated and treated with CoPP. Serum samples were obtained immediately prior to sacrifice. P< 0.01 diabetes versus control;
§§P< 0.01 diabetes CoPP versus diabetes. Results are mean SE, n¼ 4 in each group.As shown in Figure 4B, levels of NOx were significantly
decreased in hearts from mice with diabetes, 54.5 3.0% of
control (P< 0.05). This decrease in NOx was prevented by treatment
with CoPP, which restored levels of NO to 112.8 24.8% of controlFig. 4. A: Western blot analysis showing 3-nitrotyrosine (3-NT), b-actin and HO-1 exp
densitometry is expressed as ratio between 3-NT and the comparative protein b-actin.
Results are expressed as mean SE, n¼ 5 in each group. B: Overall nitrates and nitrites (N
with CoPP. Results are means SE, n¼ 3 and they are expressed as percent of control
versus diabetes.
JOURNAL OF CELLULAR BIOCHEMISTRY(P< 0.05 vs. untreated diabetic mice) (Fig. 4B). Treatment of
control mice with CoPP did not change levels of NOx in the heart
as compared to untreated controls (92.7 13.8% vs. 100% of
control).ression in hearts of control, diabetic mice untreated or treated with CoPP. Quantitative
P< 0.05 diabetes versus control; §P< 0.05 diabetes CoPP versus untreated diabetes.
Ox) levels in heart tissues obtained from control and diabetic mice untreated or treated
(0.49 0.09mmol/L). P< 0.05 diabetes versus control and §P< 0.05 diabetes CoPP
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EFFECT OF CoPP ON HEART pLKB1, pAMPK, pAKT, pGSK-3,
AND peNOS LEVELS
Diabetes resulted in no significant changes in AKT and AMPK but
significant decreases in both pAKT and pAMPK (Fig. 5).
Up-regulation of HO-1 by CoPP administration increased the
cardiac levels of both pAKT and pAMPK in diabetic mice (Fig. 5).
pAKT/AKT ratio decreased significantly in diabetic animals
compared to control mice (P< 0.01, Fig. 5A) and increased
significantly in CoPP-treated diabetic animals compared to
untreated diabetic mice (P< 0.05) (Fig. 5A). Similarly, a significant
decrease in the heart pAMPK/AMPK ratio was seen in diabetic mice
versus controls (P< 0.01, Fig. 5B), and CoPP treatment significantly
increased the pAMPK/AMPK ratio in the diabetic heart (P< 0.01 vs.
untreated diabetic mice, Fig. 5B).
These changes in pAKT and pAMPK levels were paralleled by a
decrease in both eNOS and peNOS(Ser 1179) levels in diabetic hearts
(Fig. 6A). The quantitative densitometry expressed as ratio between
phosphorylated and total eNOS showed significantly reduced values
in diabetic mice compared to controls (P< 0.001, Fig. 6A). CoPP
treatment enhanced both eNOS and peNOS levels, with a larger
effect on the latter, this was manifest by a significant increase in the
peNOS/eNOS ratio in CoPP-treated versus untreated diabetic mice
(P< 0.01, Fig. 6A).
In addition, GSK-3, a substrate of pAKT and pAMPK activity,
levels decreased in diabetic compared to control animals (P< 0.01,
Fig. 6B). In contrast, hearts from CoPP-treated diabetic mice,
exhibited a significant increase in pGSK-3 protein levels compared
to hearts from untreated diabetic animals (P< 0.01). pLKB1
levels expressed as the ratio of pLKB1 to LKB1 decreased in
diabetic hearts when compared to hearts isolated from control
animals (P< 0.01). CoPP-treatment produced an increase in levelsFig. 5. Western blot of total and phosphorylated (p-) forms of AKT (panel A), and AMPK
Western blot bands of HO-1 are shown as control for CoPP efficacy in HO-1 over-ex
phosphorylated and total amount of protein. P< 0.01 diabetes versus control, §P< 0.0
experiments.
1040 HO-1 SIGNALING IN CORONARY MICROCIRCULATIONof pLKB1 in diabetic mice (P< 0.01 compared to untreated
diabetic mice) to levels greater (P< 0.05) than in control animals
(Fig. 6C).
DISCUSSION
We examined coronary reactivity in the isolated heart of non-
insulin-dependent diabetic mice for up to 28 weeks following STZ
treatment. This is the first study to examine long-term changes in
coronary reactivity in diabetes. The response of coronary resistance
to different perfusion pressure regimens diverged from control in a
time-dependent manner in spite of constant values of hyper-
glycemia and insulinemia. This finding might account for
conflicting reports on type and/or magnitude of microvascular
alterations in diabetic animal models. In agreement with our
findings, Oltman et al. [2006] showed that Ach-induced response in
Zucker rats was progressively attenuated in 16- to 24-week-old and
28- to 36-week-old rats. Moreover, Nagareddy et al. [2005] reported
a gradual decreased expression of eNOS concomitant with increased
nitrotyrosine and progressive depressed response to vasoactive
agents in STZ-induced diabetes.
In the present study, vasoreactivity in control hearts was
characterized by stable coronary resistance at constant pressure
(65 mmHg) and ‘‘paradoxical’’ vasoconstriction at low pressure
(30 mmHg). In contrast, 28-week diabetic hearts showed a
progressive increase in coronary resistance at constant pressure,
up to threefold basal value, while low-pressure perfusion resulted
in vasodilation in place of vasoconstriction in control animals.
Both responses at high and low pressure in diabetic hearts were
reproduced by L-NAME infusion in healthy hearts.(panel B) expression in hearts of control, diabetic mice untreated or treated with CoPP.
pression. Quantitative densitometry for each enzyme is expressed as ratio between
5 and §§P< 0.01 diabetes CoPP versus diabetes. Each bar represents mean SE of four
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Fig. 6. A: Western blot of total and phorphorylated (p-) forms of eNOS expression in hearts of control, diabetic mice untreated or treated with CoPP. Myocardial b-actin
expression (comparative protein) is shown. Quantitative densitometry is expressed as ratio between phosphorylated and total amount of protein. P< 0.001 diabetes versus
control, §§P< 0.01 diabetes CoPP versus diabetes. Each bar represents mean SE of four experiments. B: pGSK-3(Ser 9) and b-actin expression in myocardium of control and
diabetic mice untreated or treated with CoPP. Quantitative densitometry was determined. P< 0.01 diabetes versus control, §§P< 0.01 diabetes CoPP versus diabetes. Each bar
represents mean SE of four experiments in control and CoPP-treated diabetic mice and mean SE of six experiments in diabetic group. C: Western blot of total and
phosphorylated form of LKB1 in myocardium isolated from control, diabetic, and CoPP-treated diabetic mice. Quantitative densitometry is expressed as ratio between
phosphorylated and total amount of protein. P< 0.01 diabetes versus control, §§P< 0.01 diabetes CoPP versus diabetes. Each column represents mean SE of four
experiments.‘‘Paradoxical’’ vasoconstriction in hearts from different species
of healthy animals, classifies this event as normal rather than a
disturbance in vasomotor tone control [Frame and Powell, 1976;
Canty and Klocke, 1985]. We hypothesized that, differently from a
constant pressure condition where NO seems necessary to counteract
the accumulation of an unknown vasoconstrictor, during low
pressure the vasoconstrictor originates from the NO system itself,
putatively the product of NO oxidation, peroxynitrite [Kozak et al.,
2005; Schildknecht and Ullrich, 2009].
In support of NO shortage in chronic diabetic hearts we found
decreased levels of eNOS compared to control hearts confirming
previous reports [Nagareddy et al., 2005; L’Abbate et al., 2007;
Peterson et al., 2007]. In addition, NOx levels were reduced while
3NT andO2 levels increased in diabetic hearts compared to controls.
This in spite of the likely increase in iNOS expression is already
documented in the diabetic heart [Nagareddy et al., 2005; L’Abbate
et al., 2007]. Hyperglycemia as well as ischemia enhances
endothelial O2 production leading to increased vascular formation
of the potent vasoconstrictor ONOO [Kossenjans et al., 2000].
Peroxynitrite, has been shown to oxidize the cofactor tetrahy-
drobiopterin into inactive molecules [Milstien and Katusic, 1999],
resulting in a preferential increase in O2 production over NO
production by eNOS activity. Thus, in the hypothesis of peroxyni-
trite being responsible for ‘‘paradoxical’’ vasoconstriction in healthy
animals, the reduction of NO production in the diabetic heart might
explain the loss of vasoconstriction seen with the prevailing effect of
ischemia-induced vasodilators such as adenosine. According to this
interpretation, we predicted that restoration of NO production and
reduction of oxidative stress in diabetic heart would normalize
microvascular reactivity. To this end we administered CoPP, whichJOURNAL OF CELLULAR BIOCHEMISTRYenhanced eNOS expression, decreased O2 and 3-NT levels, when
compared to untreated diabetic animals, and abolished both
vasoconstriction during constant pressure and vasodilation
during low pressure. At low pressure, the incomplete restoration
of ‘‘paradoxical’’ vasoconstriction in diabetic hearts after CoPP
treatment (Fig. 2C vs. inset A) contrasted with the abolition of
vasoconstriction in controls (inset Fig. 2C) with the result of almost
identical resistance profiles in CoPP-treated control and CoPP-
treated diabetic animals. This finding may be interpreted as the
result of an abnormal reduction of O2 with reduced production of
peroxynitrite in CoPP-treated controls, as opposed to partially
restored NO levels and thus increased production of peroxynitrite in
CoPP-treated diabetic animals.
We have previously showed that HO-1 attenuates O2 levels in
diabetes and improves vascular function via an increase in
extracellular superoxide dismutase [Kruger et al., 2005; Turkseven
et al., 2005]. The effects of CoPP seen here may be due, in part, to
the end-products of HO-1 activity, CO, and bilirubin. Bilirubin
scavenges ROS and inhibits activation of NADPH oxidase and
protein kinase-C, key signaling steps in oxidant-induced vascular
injury [Abraham and Kappas, 2008]. CO has no antioxidant
proprerties and its contribution to vasodilation and constriction
of microvessels remains ill defined in our experimental model.
Additionally, we reported that increases in HO-1 increase
myocardial levels of pLKB1, a serine/threonine protein kinase
working in a complex with the ‘‘pseudokinase’’ STRAD and the
protein MO25 which has been identified as an upstream activating
kinase of AMPK [Hawley et al., 2003; Woods et al., 2003]. Therefore,
HO-1 mediated increases of NO may involve pLKB1 and its
down stream signaling. A major finding of the present paper is thatHO-1 SIGNALING IN CORONARY MICROCIRCULATION 1041
Fig. 7. Hypothetical adiponectin-based mechanisms for coronary vascula-
ture control. The scheme postulates the operation of adiponectin influence on
LBK1-AMPK and PI3K/AKT pathways being negatively regulated by diabetic
condition (increased ROS) and positively regulated by HO-1 expression.STZ-induced diabetes was associated with decreased serum
adiponectin and myocardial pLKB1, pAMPK, pAKT, and HO-1
levels. All the above alterations were reversed to levels observed in
control animals by pre-treatment with CoPP. The HO-1 mediated
decreases in ROS resulted in increased adiponectin and activation of
pathways involving pLKB1, pAMPK, and pAKT (Fig. 7).
Reduced plasma adiponectin levels have been reported in patients
with coronary artery disease and diabetes, presumably as a result of
increased ROS [Ohashi et al., 2006; Wang and Scherer, 2008].
Adiponectin is critical for endothelial cell survival and function via
activation of eNOS and crosstalk between pAKT and pAMPK [Ouchi
et al., 2004; Wang and Scherer, 2008]. Crosstalk between AMPK-
AKT via pLKB1 is considered an important metabolic response
necessary to attenuate ROS-mediated endothelial dysfunction
[Schulz et al., 2008]. As both pAMPK and pAKT use eNOS as a
substrate and enhance the levels of peNOS [Chen et al., 1999;
Dimmeler et al., 1999; Abraham and Kappas, 2008], increased HO-1
expression becomes a key regulator of peNOS levels. Indeed when
pAMPK and pAKT are increased peNOS is also increased [Fulton
et al., 1999; Go et al., 2001]. We propose that the activated
pLKB1, pAMPK-pAKT system observed in CoPP-treated diabetic
hearts, could be reflected in the vessels by up-regulation of NO
bioavailability and reduction of ROS (Fig. 7).
These results provide the first indication that increased LKB1
functions as a master upstream protein kinase regulating not only
AMPK but also a subfamily of related kinases via an increase in HO-
1. Activation of LKB1-AMPK is also important in cellular energy
homeostasis via stimulation of glucose transport, switching off
energy consumption by decreasing lipogenesis, increasing fatty acid1042 HO-1 SIGNALING IN CORONARY MICROCIRCULATIONoxidation and ATP [Tomas et al., 2002; Dyck and Lopaschuk, 2006].
Accordingly we measured pGSK-3 in our cardiac tissue as an
internal control of AMPK and AKT activation; increased levels of
pAMPK and pAKT were accompanied by increased pGSK-3 levels in
treated diabetic mice.
Finally, glucose intolerance in our diabetic model deserves a
comment. Increased insulin sensitivity which paralleled HO-1 over-
expression may be related to several factors among which are the
AKT mediated increase in glucose uptake and the reduction of
oxidative stress. It should also be noted that, in addition to the
reduced number of pancreatic b-cells, STZ affects glucose transport
in skeletal muscle [Ramlal et al., 1989; Dimitrakoudis et al., 1992]
through a decrease in the number of glucose transporters. These
perturbations can be restored by increased expression of HO-1 and
increased adiponectin levels. Moreover, Mose´n et al. [2006]
described a positive action of CO on glucose-stimulated insulin
release in beta-cells, which might explain the lower glucose levels
observed during the glucose tolerance test in CoPP-treated animals
compared to untreated animals, in both control and diabetic mice.
Tissue assays in the present study was performed in hearts
subjected to 80 min Langendorff perfusion and the results could be
biased, at least in part, by experimental conditions. Similarly,
the absence of tissue assays in L-NAME-treated hearts prevented the
clarification of the possible effect of NO via HO-1-mediated
activation of pLKB1 and its downstream signal including pAMPK/
pAKT axis. In addition, tissue assays were performed in heart tissue
homogenate and the results cannot be assigned entirely to the
vascular component. However, drugs which increase pAMPK in
vivo, in muscle and myocytes [Al-Khalili et al., 2004; LeBrasseur
et al., 2006] also increase pAMPK in the vascular system [Ouchi
et al., 2004; Rodella et al., 2008].
A further limitation is the lack of measurement of iNOS
expression in tissue samples. Under normal conditions, NO is
produced by eNOS; however, iNOS is also expressed in cardiomyo-
cytes from diabetic rats. Nagareddy et al. already reported decreased
eNOS levels as opposed to increased iNOS levels in diabetic animals.
We also showed the same pattern in the heart of mildly diabetic rats
and its reversal to normal by HO-1 over-expression [L’Abbate et al.,
2007]. In the present study, a putative increased expression of iNOS
is compatible with the increased 3-nitrotyrosine levels observed in
diabetic animals as well as with the overall reduction of NOx, which
can be attributed to the scavenging of NO by superoxide as well
as to peroxynitrite-induced deficiency of tetrahydrobiopterin.
Further studies are required in order to understand the role of the
eNOS/iNOS balance in coronary vasoconstriction by the use of
specific inhibitors of iNOS as well as by tissue measurements timed
for the different phases of the experiment (baseline, ischemia,
reperfusion). The compartimentalization of NOS isoforms should
also be considered as a further confounding factor in the use of
tissue homogenates.
Finally, the meaning of the abolition of paradoxical vasocon-
striction in chronic diabetes remains to be established. Paradoxical
vasoconstriction has been interpreted as a mechanism to divert
blood from less towards better perfused myocardium [Sambuceti
et al., 2005], however, the effects of the loss of such a response has
not been investigated.JOURNAL OF CELLULAR BIOCHEMISTRY
CONCLUSION
In the present study the key event is HO-1 induction and increased
HO activity that is associated with increases in adiponectin, pAMPK,
pAKT, and peNOS levels. The study clearly demonstrates the
existence of an HO-1-adiponectin regulatory axis that can be
manipulated to enhance the crosstalk between pAKT-pAMPK
signaling pathways. The consequent increase in both NO production
and bioavailability is critical for microvascular function in our
diabetic model. Thus, the effect of CoPP-treatment that we observed
has to be considered to be the result of both local and systemic
effects that results in the restoration of microvascular function in the
hearts of diabetic mice.
In examining novel pharmacological strategies for the treatment
of diabetes, it should be emphasized that the pharmacological
targeting of HO-1 can be achieved by statins and apolipoproteins A1
mimetics [Abraham and Kappas, 2008] and the effect of CoPP can be
mimicked by the CO releasing molecules [Rodella et al., 2008]
suggesting that this approach merits further study.ACKNOWLEDGMENTS
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